Beta-thalassaemia: trait, intermedia, and major — the AU general practice guide

What beta-thalassaemia is

Beta-thalassaemia is an inherited disorder of beta-globin (HBB gene, chromosome 11) synthesis. Mutations reduce (β⁺) or abolish (β⁰) beta-globin chain production. Unpaired alpha-chains accumulate in developing red blood cells, causing them to self-destruct before leaving the bone marrow — a process called ineffective erythropoiesis — and to haemolyse prematurely in the circulation.

The body compensates by expanding the bone marrow into cortical bone and other sites (extramedullary haematopoiesis), and by absorbing far more iron from the gut than normal. Over time, iron accumulates in the heart, liver, pancreas, pituitary, and other organs regardless of how much blood has been transfused — because the drive to absorb iron comes from the ineffective erythropoiesis itself, not only from transfusions.

Three clinical phenotypes arise depending on which HBB mutations are inherited:

• Beta-thalassaemia major (Cooley’s anaemia) — two severe or null mutations; transfusion-dependent from infancy
• Beta-thalassaemia intermedia — variable; often not transfusion-dependent, but with chronic anaemia and iron loading
• Beta-thalassaemia trait (minor, carrier) — one mutation; mild microcytic anaemia, largely asymptomatic; its clinical significance is reproductive

A. Core clinical — the AU general practice framework

Who carries thalassaemia trait in Australia?

Thalassaemia trait prevalence is approximately 5–10% among individuals of Mediterranean (Italian, Greek, Maltese, Cypriot), Middle Eastern, South-East Asian (Vietnamese, Cambodian, Thai, southern Chinese), South Asian (Indian, Sri Lankan, Bangladeshi, Pakistani), and sub-Saharan African ancestry. Nationally, an estimated 50,000 carriers live in Australia, a number growing with migration from high-prevalence regions. About 500 Australians have transfusion-dependent thalassaemia.

Newborn screening for haemoglobinopathies is universal in New South Wales and Victoria via heel-prick; elsewhere it is targeted. A child born in Queensland or Western Australia to parents from a high-prevalence background may not have been screened at birth — ask the family.

Recognising thalassaemia trait in general practice

The typical presentation is an incidental finding of mild microcytic anaemia on routine bloods. Key features:

• Low MCV (typically 60–70 fL)
• Normal or elevated RBC count — the bone marrow compensates with more cells, even if each is smaller
• Mentzer index (MCV ÷ RBC count) < 13 — values below 13 favour thalassaemia, above 13 favour iron deficiency
• Normal or slightly low haemoglobin (typically 100–120 g/L)
• Normal ferritin — unless coexisting iron deficiency
• HbA2 > 3.5% on haemoglobin electrophoresis or HPLC — the diagnostic confirmation

The critical clinical trap: giving iron supplements to a patient with thalassaemia trait who appears iron-deficient on the blood count. Unsupervised iron loading worsens the already-present tendency to iron accumulation. Only supplement iron when ferritin is genuinely low.

Diagnosis and workup

In general practice:

• FBC with film: microcytic, hypochromic, target cells, occasional basophilic stippling
• Iron studies including ferritin — to exclude coexisting iron deficiency before interpreting HbA2
• Haemoglobin electrophoresis or HPLC — HbA2 > 3.5% confirms beta-thalassaemia trait
• LFTs, UEC, LDH, bilirubin — baseline

Specialist pathway (haematology or clinical genetics):

• HBB gene sequencing for definitive genotyping (MBS items 73296/73297) — required for counselling couples both carrying trait
• Alpha-globin gene analysis to identify coexisting alpha-thalassaemia, which modifies the phenotype

Differentiating from iron deficiency anaemia

Feature	Thalassaemia trait	Iron deficiency
MCV	Very low (often 60–70 fL)	Low but usually >70 fL
RBC count	Normal or elevated	Low or normal
Mentzer index	<13	>13
Ferritin	Normal	Low
HbA2	>3.5%	Normal (or falsely low in severe IDA)
RDW	Normal to mildly elevated	Usually elevated

B. Evidence for treatment — from trait to major

Beta-thalassaemia trait: counselling and no iron

Management of thalassaemia trait is primarily genetic counselling and reproductive planning, not medical treatment:

• Confirm and document the diagnosis with haemoglobin electrophoresis
• Advise no iron supplementation unless ferritin is confirmed low
• Screen the partner’s blood count and, if MCV is low, offer haemoglobin electrophoresis before conception
• When both partners carry beta-thalassaemia trait, refer to clinical genetics and discuss prenatal diagnosis options per RANZCOG guidelines
• Folate 5 mg daily in pregnancy due to the increased erythropoietic demand

Transfusion-dependent thalassaemia: regular transfusions and iron chelation

The cornerstone of thalassaemia major management is TIF 2021 guidelines:

Regular RBC transfusion every 2–4 weeks targeting a pre-transfusion haemoglobin of 9–10.5 g/dL. This suppresses the ineffective erythropoiesis that drives skeletal expansion, iron hyperabsorption, and organ damage.

Iron chelation — initiated once ferritin exceeds 1000 micrograms per litre or after approximately 10–20 lifetime transfusions:

• Deferasirox (Exjade, Jadenu) — oral once-daily; PBS Authority Section 100; monitor UEC, LFTs, hearing, vision
• Deferiprone — oral three times daily; strong myocardial iron clearance; weekly FBC mandatory for agranulocytosis risk; PBS Authority Section 100
• Deferoxamine — subcutaneous infusion nightly; PBS Authority Section 100; ototoxicity and retinopathy monitoring; adherence-limiting but still used in combination therapy for severe cardiac iron

Cardiac MRI T2* and hepatic MRI T2* annually guide chelation intensity — cardiac T2* below 10 ms indicates severe iron loading requiring intensified chelation.

Luspatercept (Reblozyl) — reducing transfusion burden

The BELIEVE trial (Cappellini, NEJM 2020) showed luspatercept 1.0–1.25 mg/kg subcutaneously every three weeks reduced transfusion burden by at least one-third in 38% of patients versus 13% with placebo. It is approved on the PBS under Section 100 for transfusion-dependent thalassaemia and, following the BEYOND trial (Piga, Lancet Haematol 2023), also for symptomatic non-transfusion-dependent thalassaemia.

Curative approaches

Haematopoietic stem-cell transplant (HSCT) — best outcomes with a matched sibling donor; event-free survival approaches 90% in low-risk (younger, well-chelated) patients (Lucarelli, Blood 2002). Outcomes are better in children than adults.

Gene therapy — betibeglogene autotemcel (Zynteglo, beti-cel) received FDA approval in August 2022 and CRISPR-based exa-cel (Casgevy) received FDA approval in January 2024 for eligible transfusion-dependent thalassaemia. Australian access is via international referral pending TGA-PBS pathway establishment; this field is evolving rapidly.

C. Organ-specific complications and surveillance

Iron overload in transfusion-dependent thalassaemia damages multiple organ systems if chelation is suboptimal. Annual surveillance by the haematology team includes:

• Cardiac — MRI T2* for myocardial iron; echocardiogram for pulmonary hypertension and LV function
• Hepatic — MRI T2* for liver iron concentration (LIC); viral hepatitis serology; 6-monthly ultrasound and AFP if cirrhotic
• Endocrine — thyroid function, fasting glucose and HbA1c, 8 am cortisol, LH/FSH and gonadal hormones, vitamin D, calcium and PTH; GH/IGF-1 in growth-delayed children
• Bone — DEXA scan every 2 years; calcium and vitamin D supplementation; bisphosphonate or denosumab for osteoporosis
• Fertility — hypogonadotrophic hypogonadism from pituitary siderosis is common in poorly chelated adults; endocrine referral for hormone replacement; fertility preservation before HSCT

Hepatitis B vaccination and catch-up is standard for all thalassaemia patients who are not immune. Hepatitis C treatment with direct-acting antivirals is high priority given the cumulative risk of cirrhosis and hepatocellular carcinoma from co-existing viral and iron hepatotoxicity.

D. Australian operations

MBS items

• Standard consults — 23/36/44
• FBC — 65070; ferritin — 66596
• HBB gene sequencing — 73296/73297 via haematology or clinical genetics with pre-test counselling
• DEXA — 12306
• GP Chronic Condition Management Plan — 965/967 for ongoing shared care coordination
• Telehealth — 91790 series for rural patients accessing specialist care remotely

PBS access for chelation

• Deferasirox (Exjade, Jadenu) — PBS Authority Section 100 (Highly Specialised Drugs)
• Deferiprone — PBS Authority Section 100
• Deferoxamine — PBS Authority Section 100
• Luspatercept (Reblozyl) — PBS Authority Section 100; specialist-initiated only

Patient support

• Thalassaemia & Sickle Cell Disorders Foundation Australia — peer support, genetic counselling resources, state-based services
• Australian Red Cross Lifeblood — transfusion coordination
• HealthDirect — Thalassaemia
• Better Health Channel — Thalassaemia

E. Special populations

Pregnancy and preconception. Women with thalassaemia major contemplating pregnancy need specialist review of chelation agents before conception — deferasirox and deferiprone are generally discontinued, with deferoxamine acceptable from the second trimester under specialist guidance. Cardiac assessment including MRI T2* is essential pre-pregnancy. Low-molecular-weight heparin prophylaxis is standard post-splenectomy in pregnancy.

Splenectomised patients. Splenectomy is now rarely performed but many older patients are already asplenic. Asplenia creates a lifelong risk of overwhelming bacterial infection (pneumococcus, meningococcus, Haemophilus influenzae b, encapsulated organisms). All splenectomised patients need pneumococcal, meningococcal, and Hib vaccinations per ATAGI guidelines, annual influenza, and lifelong education about urgent early treatment of febrile illness.

Adolescent transition. The transition from paediatric to adult haematology services is a documented high-risk period for treatment non-adherence and deterioration. GPs can support the transition by coordinating shared-care plans, maintaining regular contact, and flagging psychological concerns.

Cultural considerations. Thalassaemia disproportionately affects families from Mediterranean and South-East Asian backgrounds. Multilingual resources are available through the Thalassaemia Foundation. Communication about carrier status, prenatal diagnosis, and reproductive decisions should be approached sensitively and with professional interpreter support when English is not the first language.

When to escalate

Refer to or discuss with haematology when:

• Any patient with thalassaemia major or intermedia — these conditions require specialist-led management
• Newly diagnosed thalassaemia trait in an individual with a partner from a high-prevalence background considering conception
• Unexpected haemolytic crisis or deterioration in a known carrier
• Ferritin above 1000 micrograms per litre without existing chelation plan
• Suspected transition from intermedia to transfusion-dependent phenotype

What this article is and is not

This is general health information drawn from Therapeutic Guidelines (eTG), Thalassaemia International Federation 2021 guidelines, RANZCOG prenatal guidance, and peer-reviewed trial evidence. It is not personal medical advice and does not replace specialist haematology input. Decisions about specific treatment — including chelation agents, transfusion targets, and reproductive options — are made with the haematology team and other specialist clinicians.

For patient resources: Thalassaemia & Sickle Cell Disorders Foundation Australia, HealthDirect, Better Health Channel.

---

Sources cited

1. Thalassaemia International Federation — TDT Guidelines 4th ed. 2021
2. Therapeutic Guidelines (eTG) — Haemoglobinopathies
3. Australian Medicines Handbook (AMH)
4. RANZCOG — Prenatal screening for haemoglobinopathies
5. ATAGI — Vaccination for immunocompromised patients
6. Cappellini MD et al. — BELIEVE trial (NEJM 2020)
7. Piga A et al. — BEYOND trial (Lancet Haematol 2023)
8. Locatelli F et al. — Beti-cel gene therapy (NEJM 2024)
9. Thalassaemia & Sickle Cell Disorders Foundation Australia
10. HealthDirect — Thalassaemia